Next |
home / stock / vir / vir message board
Subject | By | Source | When |
---|---|---|---|
48w VIR-2219 +peg-IFN>31% HBs seroconverion: | DewDiligence | investorshub | 11/06/2022 11:32:58 PM |
$VIR EASL presentations: | DewDiligence | investorshub | 06/25/2022 7:50:22 PM |
$VIR HBV webcast slides: | DewDiligence | investorshub | 04/27/2022 4:03:27 PM |
$VIR -14% on amended Sotrovimab EUA due to | DewDiligence | investorshub | 03/25/2022 8:28:36 PM |
$VIR 4Q21 results: | DewDiligence | investorshub | 02/24/2022 9:25:27 PM |
VIRs 2022 HBV newsflow: | DewDiligence | investorshub | 02/24/2022 9:23:46 PM |
Up so far on another Biotech down day | rwwest | investorshub | 01/21/2022 5:45:54 PM |
VIR slide set from $JPM: | DewDiligence | investorshub | 01/11/2022 6:45:08 PM |
VIR/$GILD start phase-2 trial testing quadruple regimen of | DewDiligence | investorshub | 12/09/2021 3:06:10 PM |
Loaded again. After omicron news all weekend this | HokieHead | investorshub | 12/03/2021 4:58:52 PM |
In $46, omicron play. | HokieHead | investorshub | 12/02/2021 8:19:15 PM |
$VIR starts HBV combination trial of $VIR-2218 and $VIR-3434: | DewDiligence | investorshub | 07/15/2021 4:34:13 PM |
VIR -6% on VIR-2218 and VIR-3434 monotherapy data | DewDiligence | investorshub | 06/25/2021 2:31:45 PM |
profound efficacy. Vir Biotechnology and $GSK plan to | level42 | investorshub | 03/11/2021 10:35:51 PM |
Too high too fast. Very typical price movement. | interloper | investorshub | 01/29/2021 6:44:43 PM |
why is $VIR coming back down??? | dealerschool2006 | investorshub | 01/28/2021 4:29:24 PM |
Huge disappointment. | rtrstock | investorshub | 01/27/2021 8:40:09 PM |
Two New Rockships Taking Off After$ VIR Behold!$ FNMA | CatBirdSeat | investorshub | 01/27/2021 5:12:58 PM |
I Should have sold at 140.00 | rtrstock | investorshub | 01/27/2021 4:58:34 PM |
Full of crap haha | Srhogan1984 | investorshub | 01/27/2021 2:55:41 AM |
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NYSE Market:
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 b...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the ...
Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the ...